ALLO Valuation

Allogene Therapeutics Inc

Add to Watchlist

Advanced Chart

1.180

-0.06(-4.839%)1D

ALLO Relative Valuation

ALLO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALLO is overvalued; if below, it's undervalued.

Historical Valuation

Allogene Therapeutics Inc (ALLO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.18 is considered Undervalued compared with the five-year average of -4.70. The fair price of Allogene Therapeutics Inc (ALLO) is between 5030.51 to 24498.59 according to relative valuation methord. Compared to the current price of 1.18 USD , Allogene Therapeutics Inc is Undervalued By 99.98%.

Relative Value

Fair Zone

5030.51-24498.59

Current Price：1.18

99.98%

Undervalued

-1.23

Trailing

Forward

-0.41

EV/EBITDA

Allogene Therapeutics Inc. (ALLO) has a current EV/EBITDA of -0.41. The 5-year average EV/EBITDA is -3.51. The thresholds are as follows: Strongly Undervalued below -11.95, Undervalued between -11.95 and -7.73, Fairly Valued between 0.70 and -7.73, Overvalued between 0.70 and 4.92, and Strongly Overvalued above 4.92. The current Forward EV/EBITDA of -0.41 falls within the Historic Trend Line -Fairly Valued range.

-0.41

EV/EBIT

Allogene Therapeutics Inc. (ALLO) has a current EV/EBIT of -0.41. The 5-year average EV/EBIT is -3.38. The thresholds are as follows: Strongly Undervalued below -11.54, Undervalued between -11.54 and -7.46, Fairly Valued between 0.70 and -7.46, Overvalued between 0.70 and 4.78, and Strongly Overvalued above 4.78. The current Forward EV/EBIT of -0.41 falls within the Historic Trend Line -Fairly Valued range.

1.18

Allogene Therapeutics Inc. (ALLO) has a current PS of 1.18. The 5-year average PS is 28451.92. The thresholds are as follows: Strongly Undervalued below -128460.76, Undervalued between -128460.76 and -50004.42, Fairly Valued between 106908.27 and -50004.42, Overvalued between 106908.27 and 185364.61, and Strongly Overvalued above 185364.61. The current Forward PS of 1.18 falls within the Historic Trend Line -Fairly Valued range.

-1.60

P/OCF

Allogene Therapeutics Inc. (ALLO) has a current P/OCF of -1.60. The 5-year average P/OCF is -6.55. The thresholds are as follows: Strongly Undervalued below -19.52, Undervalued between -19.52 and -13.03, Fairly Valued between -0.07 and -13.03, Overvalued between -0.07 and 6.41, and Strongly Overvalued above 6.41. The current Forward P/OCF of -1.60 falls within the Historic Trend Line -Fairly Valued range.

-1.53

P/FCF

Allogene Therapeutics Inc. (ALLO) has a current P/FCF of -1.53. The 5-year average P/FCF is -6.32. The thresholds are as follows: Strongly Undervalued below -18.70, Undervalued between -18.70 and -12.51, Fairly Valued between -0.13 and -12.51, Overvalued between -0.13 and 6.07, and Strongly Overvalued above 6.07. The current Forward P/FCF of -1.53 falls within the Historic Trend Line -Fairly Valued range.

Allogene Therapeutics Inc (ALLO) has a current Price-to-Book (P/B) ratio of 0.75. Compared to its 3-year average P/B ratio of 1.09 , the current P/B ratio is approximately -30.64% higher. Relative to its 5-year average P/B ratio of 1.79, the current P/B ratio is about -57.95% higher. Allogene Therapeutics Inc (ALLO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -42.68%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -29.15% , the current FCF yield is about -100.00% lower.

0.75

P/B

Median3y

1.09

Median5y

1.79

0.00

FCF Yield

Median3y

-42.68

Median5y

-29.15

Competitors Valuation Multiple

The average P/S ratio for ALLO's competitors is 4.75, providing a benchmark for relative valuation. Allogene Therapeutics Inc Corp (ALLO) exhibits a P/S ratio of 1.18, which is -75.18% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ALLO.O

Allogene Therapeutics Inc

Entrada Therapeutics Inc

Voyager Therapeutics Inc

Candel Therapeutics Inc

5.22

286.55M

Performance Decomposition

Market capitalization of ALLO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ALLO in the past 1 year is driven by Unknown.